- Home
- DWTX vs IMRN Comparison
DWTX vs IMRN Comparison
Compare DWTX & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DWTX
- IMRN
- Stock Information
- Founded
- DWTX 2012
- IMRN 1994
- Country
- DWTX United States
- IMRN Australia
- Employees
- DWTX N/A
- IMRN N/A
- Industry
- DWTX
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- DWTX
- IMRN Health Care
- Exchange
- DWTX NYSE
- IMRN Nasdaq
- Market Cap
- DWTX 9.2M
- IMRN 9.2M
- IPO Year
- DWTX N/A
- IMRN N/A
- Fundamental
- Price
- DWTX $4.95
- IMRN $1.70
- Analyst Decision
- DWTX Strong Buy
- IMRN Strong Buy
- Analyst Count
- DWTX 1
- IMRN 1
- Target Price
- DWTX $10.00
- IMRN $5.00
- AVG Volume (30 Days)
- DWTX 39.8K
- IMRN 24.0K
- Earning Date
- DWTX 08-14-2025
- IMRN 07-07-2025
- Dividend Yield
- DWTX N/A
- IMRN N/A
- EPS Growth
- DWTX N/A
- IMRN N/A
- EPS
- DWTX N/A
- IMRN N/A
- Revenue
- DWTX N/A
- IMRN $4,048,286.00
- Revenue This Year
- DWTX N/A
- IMRN N/A
- Revenue Next Year
- DWTX N/A
- IMRN N/A
- P/E Ratio
- DWTX N/A
- IMRN N/A
- Revenue Growth
- DWTX N/A
- IMRN 82.90
- 52 Week Low
- DWTX $1.62
- IMRN $1.50
- 52 Week High
- DWTX $29.28
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- DWTX N/A
- IMRN 35.44
- Support Level
- DWTX N/A
- IMRN $1.82
- Resistance Level
- DWTX N/A
- IMRN $1.96
- Average True Range (ATR)
- DWTX 0.00
- IMRN 0.11
- MACD
- DWTX 0.00
- IMRN -0.01
- Stochastic Oscillator
- DWTX 0.00
- IMRN 7.50
About DWTX DOGWOOD THERAPEUTICS INC
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.